ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

AGY Allergy Therapeutics Plc

2.875
0.00 (0.00%)
02 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Allergy Therapeutics Plc LSE:AGY London Ordinary Share GB00B02LCQ05 ORD 0.1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 2.875 2.75 3.00 2.875 2.875 2.88 973,172 08:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations 59.59M -43.07M -0.0090 -3.19 136.8M
Allergy Therapeutics Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker AGY. The last closing price for Allergy Therapeutics was 2.88p. Over the last year, Allergy Therapeutics shares have traded in a share price range of 0.85p to 3.80p.

Allergy Therapeutics currently has 4,766,439,938 shares in issue. The market capitalisation of Allergy Therapeutics is £136.80 million. Allergy Therapeutics has a price to earnings ratio (PE ratio) of -3.19.

Allergy Therapeutics Share Discussion Threads

Showing 4951 to 4973 of 5000 messages
Chat Pages: 200  199  198  197  196  195  194  193  192  191  190  189  Older
DateSubjectAuthorDiscuss
13/3/2024
12:31
Coinbase, Jimmy, I am as keen as any of you that AGY should finally escape its period of bad luck (partly caused by atrocious management - but that's a different matter, one Skygem surely must be asking themselves about) and notch up a few clinical achievements. I also agree that the news from the clinic has been good. However:
1) I am underwhelmed at the reaction to the success of G306 announced in November (! 4 months ago!!)- which should occasion the start of final MA approvals and possibly of licensing / M&A activity; it raises questions about management competence that nothing seems afoot at all on this, a target the company has been aiming at since its foundation and
2) this recent Peanut announcement - extremely limited exposure with primarily safety objectives and some blood-chemistry. Highly promising though it is, it's all super-preliminary and represents the very start of the process that G306 supposedly represented the end of.
I agree with you that there is great upside potential here but weighing on this are a) the issue of rudimentary management competence and b) the future financing needs which might turn out badly for us minor shareholders after resolutions 11-14 passed at the AGM.

vergeltung
13/3/2024
11:45
Coin
We are aligned. Yesterdays news on tolerability and using biomarkers was very reassuring.

Commercialisation news is what the market needs as does Skygem :-)

jimmyloser
13/3/2024
11:34
Jimmyloser, we’ll know one way or another by the end of the month. If they don’t kill anyone and the EMA look kindly on them then it’ll explode.
coinbase
13/3/2024
10:17
I came across this and to me it was an eye opener and shows a small sample of the brains involved and people developing this much needed product.

A product for peanut allergic reaction is much needed but the market I would suggest for food allergic reaction must surely be a much bigger prize commercially. However, the news that should see this start to move (impo) is the response from the likes of the FDA.

Whilst I have skin in AGY's succesful transformation and keep an eye on it, I'll wager that huge corporation's are all watching even closer.....again impo.

Fingers firmly crossed. DYOR ETC

jimmyloser
12/3/2024
09:25
“First patient receives subcutaneous dosing with no safety signals observed” says it all.
coinbase
12/3/2024
07:42
Allergy Therapeutics commences subcutaneous dosing in peanut allergic patients in Phase I/IIa VLP Peanut PROTECT Trial - hXXps://www.londonstockexchange.com/news-article/AGY/vlp-peanut-protect-trial-update/16372281
coinbase
11/3/2024
16:57
?Read the runes :
jimmyloser
11/3/2024
07:57
Another piece of confidence this morning impo, and strengthening of the executive board.

Good work.

jimmyloser
05/3/2024
17:16
Smacks of confidence impo

The programme of continuous improvement across the supply chain and quality systems paving the way for.......... 'increased capacity' is ongoing and is a multi-year project.

jimmyloser
05/3/2024
13:22
I have done the same. Not to-day though.

I know you will be aware, but for others, the 2.42p are sells.

jimmyloser
05/3/2024
13:11
Someone's gearing up.
coinbase
05/3/2024
13:03
Bed and ISA?!
coinbase
23/2/2024
12:02
DMA: 105,000 @ 2.624.
coinbase
20/2/2024
11:23
Yes, I agree. I expect this to be sold at much more than. But 5p is my next milestone by summertime.
impo

jimmyloser
20/2/2024
11:02
5 GBX is peanuts!
coinbase
20/2/2024
10:05
Thanks coin, long may it continue. I re read the mandatory offer over the weekend. I made very interesting reading.
The current price is bobbins. I continue to buy and have bought again this morning.

Somebody on here mentioned 5p a while ago and at the time I thought, not a hope.

No longer.

Patience.

impo/dyor

jimmyloser
20/2/2024
09:58
There’s a tussle going on behind the scenes between Panmure and Shore.
coinbase
15/2/2024
09:27
"SkyGem has, and still holds the belief that Allergy Therapeutics has the potential to become one of the most prominent allergy immunotherapy companies globally"

2.5p for a stake lovl.

impo

jimmyloser
14/2/2024
16:08
Panmure have upped the bid, narrowing the spread to 2.82%.
coinbase
14/2/2024
13:49
Thank you, April onwards. EMA/FDA/??
jimmyloser
14/2/2024
13:46
EMA = European Medicines Agency, the EU's FDA
vergeltung
14/2/2024
13:30
Well, coinbase, nothing of any real surprise there. I dont believe that we will see any movement here of any significance until April/May. I remain of the opinion that AGY is a potential blockbuster (impo) and I have been buying steadily over recent weeks including today.

I liked this from Simon Chen
"Furthermore, SkyGem believes its key relationships and capabilities within Asia can unlock additional value for Allergy Therapeutics due to the access it provides to key markets for Allergy Therapeutics' products".

Steady as she goes!

Coin, what or who are EMA?

jimmyloser
14/2/2024
07:30
Half-Year Trading Update - hXXps://www.londonstockexchange.com/news-article/AGY/half-year-trading-update-2024/16331428
coinbase
Chat Pages: 200  199  198  197  196  195  194  193  192  191  190  189  Older

Your Recent History

Delayed Upgrade Clock